Phathom Pharmaceuticals (PHAT) News Today $11.74 +0.46 (+4.08%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 8:54 AM | marketbeat.comPhathom Pharmaceuticals' (PHAT) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $26.00 target price on shares of Phathom Pharmaceuticals in a report on Friday.July 23, 2024 | markets.businessinsider.comCraig-Hallum Reaffirms Their Buy Rating on Phathom Pharmaceuticals (PHAT)July 21, 2024 | msn.comBiden Health Watch; Pediatrician Killed on Bike; Olympic Medical Team Gets UniformJuly 20, 2024 | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Given "Buy" Rating at Needham & Company LLCJuly 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and Terveystalo Oy (OtherTTALF)July 19, 2024 | marketwatch.comPhathom Gets Expanded FDA OK of Voquezna in Non-Erosive GERDJuly 19, 2024 | markets.businessinsider.comPhathom Pharma's Voquezna 10 Mg Gets FDA Approval For Non-erosive GERDJuly 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Phathom Pharmaceuticals Amid Voquezna’s NERD Indication Approval and Robust Sales ForecastJuly 19, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 7.2%Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 7.2%July 19, 2024 | americanbankingnews.comPhathom Pharmaceuticals' (PHAT) Buy Rating Reiterated at HC WainwrightJuly 19, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Receives "Buy" Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $26.00 price objective on shares of Phathom Pharmaceuticals in a research report on Friday.July 19, 2024 | americanbankingnews.comAzmi Nabulsi Sells 10,901 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) StockJuly 19, 2024 | americanbankingnews.comInsider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Sells 33,848 Shares of StockJuly 19, 2024 | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 5.8% After Insider SellingJuly 18, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 5.8% on Insider SellingPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 5.8% After Insider SellingJuly 18, 2024 | insidertrades.comMolly Henderson Sells 4,325 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) StockJuly 18, 2024 | globenewswire.comPhathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in AdultsJuly 18, 2024 | insidertrades.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Sells $127,759.72 in StockJuly 16, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up to $12.67Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up to $12.67July 11, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 11.4%Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 11.4%July 9, 2024 | marketbeat.comJennison Associates LLC Acquires Shares of 1,647,697 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Jennison Associates LLC bought a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,647,697 shares ofJuly 8, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $26.00 price target on shares of Phathom Pharmaceuticals in a report on Monday.July 2, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 8%Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 8%June 26, 2024 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Purchased by Medicxi Ventures Management Jersey LtdMedicxi Ventures Management Jersey Ltd grew its holdings in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 98.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,464,572 shares of the company's stocJune 26, 2024 | seekingalpha.comPhathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating DelaysJune 21, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.9%Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 6.9%June 18, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading 7.9% Higher Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 7.9%June 11, 2024 | marketbeat.comAvidity Partners Management LP Buys 104,280 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Avidity Partners Management LP lifted its holdings in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 6.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,721,580 shares of the company's stock afterJune 9, 2024 | marketbeat.comCatalys Pacific LLC Makes New Investment in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Catalys Pacific LLC purchased a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 721,962 shares of the company'sJune 7, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $26.00 price target on shares of Phathom Pharmaceuticals in a research note on Friday.June 7, 2024 | investorplace.comRide the Gamma Wave: 3 Stocks on the Verge of a Short SqueezeJune 6, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6%Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 6%June 3, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading 8.1% Higher Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 8.1%May 30, 2024 | marketbeat.comDecheng Capital LLC Purchases Shares of 850,000 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Decheng Capital LLC purchased a new stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 850,000 shares of the company'sMay 28, 2024 | globenewswire.comPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 25, 2024 | markets.businessinsider.comStrong Market Uptake of Phathom Pharmaceuticals’ V oquezna Signals Promising GrowthMay 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Cara Therapeutics (CARA)May 17, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $26.00 price target on shares of Phathom Pharmaceuticals in a research report on Friday.May 15, 2024 | finance.yahoo.comPhathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual MeetingMay 14, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 8.7%Phathom Pharmaceuticals (NASDAQ:PHAT) Trading 8.7% HigherMay 13, 2024 | finance.yahoo.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call TranscriptMay 10, 2024 | investorplace.comThe 3 Best Healthcare Stocks to Buy in May 2024May 9, 2024 | globenewswire.comPhathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Phathom Pharmaceuticals Amid Voquezna Launch and Promising Pipeline DevelopmentsMay 7, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Apellis Pharmaceuticals Amid Strong Syfovre Sales and Robust Financial OutlookMay 7, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 5.9%Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 5.9%May 7, 2024 | markets.businessinsider.comOptimistic Outlook: Buy Recommendation for Stoke Therapeutics Amidst Strategic Progress and Anticipated Clinical MilestonesMay 6, 2024 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 11.8%Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 11.8%May 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Phathom Pharmaceuticals on V oquezna’s Promising Market TrajectoryMay 3, 2024 | msn.comStifel Initiates Coverage of Phathom Pharmaceuticals (PHAT) with Buy Recommendation Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address Kiss of death from Joe Biden (Ad)I did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care. I have uncovered a bombshell that changes everything… and threatens everything. PHAT Media Mentions By Week PHAT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHAT News Sentiment▼0.580.61▲Average Medical News Sentiment PHAT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHAT Articles This Week▼73▲PHAT Articles Average Week Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ORIC Pharmaceuticals News Nkarta News Innoviva News Karyopharm Therapeutics News BioXcel Therapeutics News Supernus Pharmaceuticals News Morphic News SpringWorks Therapeutics News MorphoSys News Bausch Health Companies News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHAT) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHAT Stock Alerts